R. Mamidi

发表

Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib

M. Monshouwer, I. Poggesi, L. D. De Zwart, 2021, CPT: pharmacometrics & systems pharmacology.

Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants

E. Wajs, K. Usiskin, J. Murphy, 2015, Clinical pharmacology in drug development.

Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants

P. Rothenberg, J. Murphy, H. Stieltjes, 2015, Clinical pharmacology in drug development.

Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)

F. Saad, E. Posadas, K. Chi, 2021, Cancer Chemotherapy and Pharmacology.

Successful Integration of Nonclinical and Clinical Findings in Interpreting the Clinical Relevance of Rodent Neoplasia with a New Chemical Entity

Mark D. Johnson, C. Louden, S. De Jonghe, 2015, Toxicologic pathology.

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

P. Rothenberg, E. Wajs, S. Weiner, 2014, International journal of clinical pharmacology and therapeutics.

Metabolism and Excretion of Canagliflozin in Mice, Rats, Dogs, and Humans

Mark D. Johnson, F. Cuyckens, D. C. Evans, 2014, Drug Metabolism and Disposition.

Quantitative determination of ragaglitazar in rat plasma by HPLC: validation and application in pharmacokinetic study.

R. Mullangi, R. Rajagopalan, R. Mamidi, 2002, Biomedical chromatography : BMC.

Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents.

J. Iqbal, B. Lohray, R. Chakrabarti, 2001, European journal of medicinal chemistry.

Oral bioavailability and Pharmacokinetics of PAT-5A, a new insulin sensitizer in rats

R. Mullangi, Rajagopalan Ramanujam, R. Mamidi, 2002, European Journal of Drug Metabolism and Pharmacokinetics.

Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug–Drug Interaction Study

D. Ouellet, I. Poggesi, M. De Meulder, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of an Orally Active Novel Camptothecin Analog, DRF‐1042, in Refractory Cancer Patients in a Phase I Dose Escalation Study

M. L. Srinivas, R. Digumarti, N. Srinivas, 2004, Journal of clinical pharmacology.

In vitro and physiologically‐based pharmacokinetic based assessment of drug–drug interaction potential of canagliflozin

Mark D. Johnson, L. Leclercq, S. Dallas, 2017, British journal of clinical pharmacology.

Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the Rhesus monkey

M. Bottacini, R. Mamidi, M. Kelley, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives.

B. Lohray, V. B. Lohray, Sunil Kumar, 2002, Bioorganic & medicinal chemistry.

Synthesis of conformationally constrained analogues of linezolid: structure-activity relationship (SAR) studies on selected novel tricyclic oxazolidinones.

J. Iqbal, D. Srinivas, R. Rajagopalan, 2002, Journal of medicinal chemistry.

Bioanalytical considerations for compounds containing free sulfhydryl groups.

N. Srinivas, R. Mamidi, 2003, Biomedical chromatography : BMC.

Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard.

M. Ramesh, N. Srinivas, R. Mamidi, 2003, Biomedical chromatography : BMC.

Metabolism and Excretion of RWJ-333369 [1,2-Ethanediol, 1-(2-Chlorophenyl)-, 2-carbamate, (S)-] in Mice, Rats, Rabbits, and Dogs

Mark Kao, Willem Meuldermans, Geert Mannens, 2007, Drug Metabolism and Disposition.

LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume.

Yang Yuan, Naidong Weng, David C. Evans, 2013, Journal of pharmaceutical and biomedical analysis.

In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans

R. Favis, D. Devineni, E. Scheers, 2015, Journal of clinical pharmacology.

Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib

J. Monbaliu, T. Verhaeghe, R. Mamidi, 2007, Cancer Chemotherapy and Pharmacology.

Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokinetics.

N. Srinivas, V. V. Upreti, R. Mamidi, 2003, Biomedical chromatography : BMC.

Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

Alfred P. Tonelli, M. Fung, A. Tonelli, 2010, Cancer Chemotherapy and Pharmacology.

Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib.

J. Monbaliu, T. Verhaeghe, L. van Beijsterveldt, 2007, Cancer chemotherapy and pharmacology.

De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes.

Honghui Zhou, S. Dallas, M. Markowska, 2012, Current drug metabolism.

Safety, Tolerability, and Pharmacokinetics of a Capsule Formulation of DRF‐1042, a Novel Camptothecin Analog, in Refractory Cancer Patients in a Bridging Phase I Study

R. Digumarti, N. Srinivas, R. Mullangi, 2005, Journal of clinical pharmacology.

Polymorphism of dextromethorphan oxidation in South Indian subjects

R. Mamidi, K. Katneni, S. Vakkalanka, 1999, Clinical pharmacology and therapeutics.

Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor

I. Poggesi, L. Leclercq, F. Cuyckens, 2020, Xenobiotica; the fate of foreign compounds in biological systems.

Cell-based models to study hepatic drug metabolism and enzyme induction in humans

Willem Meuldermans, Geert Mannens, D. Roymans, 2005, Expert opinion on drug metabolism & toxicology.

2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1-benzenesulfonamide (DRF-4367): an orally active COX-2 inhibitor identified through pharmacophoric modulation.

S. A. Rajjak, R. Mullangi, Rajagopalan Ramanujam, 2004, Organic & biomolecular chemistry.

Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.

Mark D. Johnson, H. Geys, B. Feyen, 2014, Chemico-biological interactions.

Sample Preparation for LC‐MS Bioanalysis of Liposomal Samples

Naidong Weng, Wenying Jian, R. Mamidi, 2019, Sample Preparation in LC‐MS Bioanalysis.

Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-N-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration.

J. Iqbal, R. Mullangi, Rajagopalan Ramanujam, 2006, Bioorganic & medicinal chemistry.

Novel euglycemic and hypolipidemic agents. 1.

B. Lohray, R. Chakrabarti, R. Vikramadithyan, 1998, Journal of medicinal chemistry.